NFSG
SEEL

Newbridge Financial Services Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Newbridge Financial Services Group’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$4 – 1198
2024
Q3 		$4 Sell
1
-1
-50% -$6 ﹤0.01% 654
2024
Q2 		$14 Hold
2
– – ﹤0.01% 1076
2024
Q1 		$118 Hold
2
– – ﹤0.01% 1142
2023
Q4 		$277 Hold
2
– – ﹤0.01% 1068
2023
Q3 		$1.1K Hold
2
– – ﹤0.01% 1148
2023
Q2 		$9.56K Hold
2
– – ﹤0.01% 896
2023
Q1 		$5.53K Hold
2
– – ﹤0.01% 1043
2022
Q4 		$5.43K Hold
2
– – ﹤0.01% 1052
2022
Q3 		$8K Hold
2
– – ﹤0.01% 959
2022
Q2 		$5K Hold
2
– – ﹤0.01% 1033
2022
Q1 		$7K Hold
2
– – ﹤0.01% 1036
2021
Q4 		$13K Hold
2
– – 0.01% 861
2021
Q3 		$19K Hold
2
– – 0.01% 686
2021
Q2 		$21K Hold
2
– – 0.01% 772
2021
Q1 		$40K Buy
+2
New +$23.3K 0.03% 455

Other funds holding SEEL

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
VWWMG
Vermillion & White Wealth Management Group Phoenixville, Pennsylvania $174M AUM 15.31% 1-Year Est. Return

Newbridge Financial Services Group's SEEL Position: Q4 2024 in Review

Newbridge Financial Services Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2024, closing a stake of 1 share — an estimated $4 sold.

Newbridge Financial Services Group first reported a position in SEEL in Q1 2021 and held it in 15 quarters. The position peaked at $40K in Q1 2021. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2024.

  • Newbridge Financial Services Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Newbridge Financial Services Group sold 1 Seelos Therapeutics, Inc. Common Stock share in Q4 2024, an estimated $4.
  • Newbridge Financial Services Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2021 and held it in 15 quarters.
  • Newbridge Financial Services Group's Seelos Therapeutics, Inc. Common Stock position peaked at $40K in Q1 2021.
  • 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Newbridge Financial Services Group's 13F filing for Q4 2024, filed 28 Jan 2025.